Eurofins Scientific SE (ERFSF) Stock Price & Analysis
Eurofins Scientific SE (ERFSF) — price $87.18 (+1.43%), as of the Oct 5, 2026 trading session; market cap $15.1B.
Educational signal · not a buy or sell recommendation · How to read this
Eurofins Scientific SE · ERFSF
Eurofins Scientific SE provides analytical testing and laboratory services globally. The company operates in diverse sectors, including agroscience, biopharma, food, environment, and consumer products.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $87.18 | |
| Change on the day | +1.43% | |
| 52-week range | $64.95 – $92.97 | |
| Market capitalisation | $15.1B | |
| Price / earnings (trailing) | 24.95 | |
| Shares traded on the day | 34 |
Price & events
Other perspectives
Council score for Eurofins Scientific SE (ERFSF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
0 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read date unavailable · not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ERFSF film — every key number, told as a short cinematic story
~2 min · open the film
What is Eurofins Scientific SE (ERFSF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Eurofins Scientific SE (ERFSF) is the company analyzed here. It employs 65,694 people and is led by Gilles G. Martin. In Q2 FY2026 it reported revenue of $4.15B and net income of $339M. The market values it at $15.1B.
What do the latest results show for Eurofins Scientific SE (ERFSF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $4.15B. Against analyst estimates the company has EPS beat 4 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $4.15B | $339M | $1.84 (diluted) |
| Q4 FY2025 | $4.13B | $256M | $1.37 (diluted) |
| Q2 FY2025 | $4.06B | $277M | $1.47 (diluted) |
| Q4 FY2024 | $3.97B | $208M | $1.07 (diluted) |
What are the financial strengths and risks for Eurofins Scientific SE (ERFSF)?
Short answer
The distress and quality screens read Altman Z 3.34 · Piotroski F 6. Trailing ratios: ROE 14.8% · ROA 4.8% · current ratio 1.13 · earnings yield 4.1% · free-cash-flow yield 5.0%.
What has been published about Eurofins Scientific SE (ERFSF)?
Investor Questions: ERFSF Stock
These answers are editorial: 1 of these 8 answers is drawn from the ERFSF research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ERFSF a good stock to buy?
Stock Expert AI does not rate ERFSF buy, sell or hold. Eurofins Scientific SE has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ERFSF stock price today?
The last price recorded on this page for Eurofins Scientific SE (ERFSF) is $87.18, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key growth opportunities for ERFSF in healthcare?
Eurofins Scientific SE has several key growth opportunities in the healthcare sector. The company can expand its biopharma testing services to capitalize on the growing biopharmaceutical industry.
What are the key factors to evaluate for ERFSF?
Evaluate ERFSF on fundamentals, analyst consensus, and risk factors. P/E: 24.95x. Eurofins can expand its presence in these markets through strategic acquisitions and partnerships. Not financial advice.
How frequently does ERFSF data refresh on this page?
ERFSF's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ERFSF's recent stock price performance?
Eurofins Scientific SE (ERFSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global presence with an extensive network of laboratories. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ERFSF overvalued or undervalued right now?
Eurofins Scientific SE (ERFSF) trades at 24.95x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ERFSF before investing?
Before investing in Eurofins Scientific SE (ERFSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (15 figures)
The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $87.18 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T20:14:20.666Z. | |
px.change | Change on the day | +1.43% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $15.1B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T19:45:37.000Z. Captured from FMP at 2026-10-05T20:14:18.782Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$1.23 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 24.95 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 34 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $4.15B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $339M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $64.95 – $92.97 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 65,694 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Gilles G. Martin | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.34 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 14.8% · ROA 4.8% · current ratio 1.13 · earnings yield 4.1% · free-cash-flow yield 5.0% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.